BACKGROUND: The incidence of dermatologic infections in patients receiving checkpoint inhibitors (CPIs) has not been systematically described. OBJECTIVE: Identify the incidence of dermatologic infections in patients who received CPIs. METHODS: Retrospective review of dermatologic infections in patients who received CPIs between 2005 and 2020 and were evaluated by dermatologists at Memorial Sloan Kettering Cancer Center. RESULTS: Of 2061 patients in the study, 1292 were actively receiving CPIs (≤ 90 days since the last dose) and 769 had previously been on CPIs (> 90 days since the last dose). The dermatologic infection rate was significantly higher in patients with active CPI treatment (17.5%) than in patients not actively being treated (8.2%; P < .0001). In patients on CPIs, 82 (36.2%), 78 (34.5%), and 48 (21.2%) had bacterial, fungal, and viral infections, respectively, and 18 (8.0%) had polymicrobial infections. Anti-cytotoxic T-lymphocyte-associated antigen-4 monotherapy was associated with the highest risk of infection (hazard ratio, 2.93; 95% confidence interval, 1.87 to 4.60; P < .001). LIMITATIONS: Retrospective design and sample limited to patients referred to dermatology. CONCLUSIONS: Patients actively receiving CPIs are more susceptible to dermatologic infections, with anti-cytotoxic T-lymphocyte-associated antigen-4 monotherapy carrying the highest risk, suggesting that the index of suspicion for infections should be increased in these patients to minimize morbidity and optimize care.
BACKGROUND: The incidence of dermatologic infections in patients receiving checkpoint inhibitors (CPIs) has not been systematically described. OBJECTIVE: Identify the incidence of dermatologic infections in patients who received CPIs. METHODS: Retrospective review of dermatologic infections in patients who received CPIs between 2005 and 2020 and were evaluated by dermatologists at Memorial Sloan Kettering Cancer Center. RESULTS: Of 2061 patients in the study, 1292 were actively receiving CPIs (≤ 90 days since the last dose) and 769 had previously been on CPIs (> 90 days since the last dose). The dermatologic infection rate was significantly higher in patients with active CPI treatment (17.5%) than in patients not actively being treated (8.2%; P < .0001). In patients on CPIs, 82 (36.2%), 78 (34.5%), and 48 (21.2%) had bacterial, fungal, and viral infections, respectively, and 18 (8.0%) had polymicrobial infections. Anti-cytotoxic T-lymphocyte-associated antigen-4 monotherapy was associated with the highest risk of infection (hazard ratio, 2.93; 95% confidence interval, 1.87 to 4.60; P < .001). LIMITATIONS: Retrospective design and sample limited to patients referred to dermatology. CONCLUSIONS: Patients actively receiving CPIs are more susceptible to dermatologic infections, with anti-cytotoxic T-lymphocyte-associated antigen-4 monotherapy carrying the highest risk, suggesting that the index of suspicion for infections should be increased in these patients to minimize morbidity and optimize care.
Authors: Rachael A Clark; Benjamin Chong; Nina Mirchandani; Nooshin K Brinster; Kei-Ichi Yamanaka; Rebecca K Dowgiert; Thomas S Kupper Journal: J Immunol Date: 2006-04-01 Impact factor: 5.422
Authors: Mario E Lacouture; Jedd D Wolchok; Gil Yosipovitch; Katharina C Kähler; Klaus J Busam; Axel Hauschild Journal: J Am Acad Dermatol Date: 2014-04-24 Impact factor: 11.527
Authors: Spencer C Wei; Jacob H Levine; Alexandria P Cogdill; Yang Zhao; Nana-Ama A S Anang; Miles C Andrews; Padmanee Sharma; Jing Wang; Jennifer A Wargo; Dana Pe'er; James P Allison Journal: Cell Date: 2017-08-10 Impact factor: 41.582
Authors: Daniel L Barber; Shunsuke Sakai; Ragini R Kudchadkar; Steven P Fling; Tracey A Day; Julie A Vergara; David Ashkin; Jonathan H Cheng; Lisa M Lundgren; Vanessa N Raabe; Colleen S Kraft; Jorge J Nieva; Martin A Cheever; Paul T Nghiem; Elad Sharon Journal: Sci Transl Med Date: 2019-01-16 Impact factor: 17.956
Authors: Kira Minkis; Benjamin C Garden; Shenhong Wu; Melissa P Pulitzer; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2013-01-26 Impact factor: 11.527
Authors: Marcus A Couey; R Bryan Bell; Ashish A Patel; Meghan C Romba; Marka R Crittenden; Brendan D Curti; Walter J Urba; Rom S Leidner Journal: J Immunother Cancer Date: 2019-07-03 Impact factor: 13.751